John L Xu

Dual Targeting of EGFR and HER2 by a Bispecific Antibody-Drug Conjugate Demonstrates Broad Antitumor Activity in Multiple Solid Tumors.

GenSci139, an EGFR×HER2 bispecific ADC, is developed and demonstrated superior antitumor efficacy over DS-8201 in multiple cell-line-derived xenograft and patient-derived xenograft models, suggesting potential for synergistic combination with immunotherapies.